Sarana Meditama Metropolitan
PT Sarana Meditama Metropolitan Tbk engages in the hospital management of EMC Hospital Pulomas in Pulomas, East Jakarta. It also is involved in trading of medical equipment; healthcare pharmacy; real estate; and agriculture. The company was founded in 1984 and is based in Jakarta, Indonesia. PT Sarana Meditama Metropolitan Tbk is a subsidiary of PT Elang Mahkota Teknologi Tbk.
Sarana Meditama Metropolitan (SAME) - Total Liabilities
Latest total liabilities as of September 2025: Rp1.60 Trillion IDR
Based on the latest financial reports, Sarana Meditama Metropolitan (SAME) has total liabilities worth Rp1.60 Trillion IDR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sarana Meditama Metropolitan - Total Liabilities Trend (2009–2024)
This chart illustrates how Sarana Meditama Metropolitan's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sarana Meditama Metropolitan Competitors by Total Liabilities
The table below lists competitors of Sarana Meditama Metropolitan ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Viatron Technologies Inc
KQ:141000
|
Korea | ₩23.43 Billion |
|
Takkt AG
XETRA:TTK
|
Germany | €408.30 Million |
|
Prelude Therapeutics Inc
NASDAQ:PRLD
|
USA | $36.22 Million |
|
Blackrock Silver Corp
OTCQX:BKRRF
|
USA | $1.28 Million |
|
Taipei Star Bank
TWO:5863
|
Taiwan | NT$87.16 Billion |
|
Thaivivat Holdings Public Company Limited
BK:TVH
|
Thailand | ฿5.50 Billion |
|
Brightek Optoelectronic Co Ltd
TW:5244
|
Taiwan | NT$833.08 Million |
|
K N Kenanga Holdings Bhd
KLSE:6483
|
Malaysia | RM6.49 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Sarana Meditama Metropolitan's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sarana Meditama Metropolitan's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sarana Meditama Metropolitan (2009–2024)
The table below shows the annual total liabilities of Sarana Meditama Metropolitan from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Rp1.42 Trillion | +2.82% |
| 2023-12-31 | Rp1.38 Trillion | +19.38% |
| 2022-12-31 | Rp1.16 Trillion | +123.76% |
| 2021-12-31 | Rp517.06 Billion | -61.52% |
| 2020-12-31 | Rp1.34 Trillion | +7.04% |
| 2019-12-31 | Rp1.26 Trillion | +4.36% |
| 2018-12-31 | Rp1.20 Trillion | +78.89% |
| 2017-12-31 | Rp672.45 Billion | +11.90% |
| 2016-12-31 | Rp600.93 Billion | +30.06% |
| 2015-12-31 | Rp462.04 Billion | +67.66% |
| 2014-12-31 | Rp275.58 Billion | +12.65% |
| 2013-12-31 | Rp244.64 Billion | -9.91% |
| 2012-12-31 | Rp271.56 Billion | -11.52% |
| 2011-12-31 | Rp306.90 Billion | -1.71% |
| 2010-12-31 | Rp312.24 Billion | +7.04% |
| 2009-12-31 | Rp291.70 Billion | -- |